MyFinsight
Home
Blog
About
Oncology Institute, Inc. (TOIIW)
Oncology Institute, Inc. (TOIIW)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,285K
Free Cash flow
-$3,257K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable
Accrued expenses and other curre...
Share-based compensation
Others
Negative Cash Flow Breakdown
Inventories
Change in fair value of liabilit...
Net loss
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Unrealized (gain) loss on investments
-
0
0
0
Accretion of discount on investment securities
-
0
0
0
Net loss
-2,492
-7,508
-16,504
-36,594
Depreciation and amortization
1,616
1,632
1,723
3,589
Deferred taxes
-
0
0
-32
Amortization of debt issuance costs and debt discount
1,211
1,205
1,172
6,003
Write-off of assets from clinical trials segment
-
0
0
2,398
Loss on disposal of property and equipment
-
0
0
0
Share-based compensation
1,686
1,317
1,024
2,210
Change in fair value of liability classified warrants
-168
1
150
96
Change in fair value of liability classified conversion option derivatives
4,996
1,067
-5,977
-7,296
Accounts receivable
-864
-641
3,980
8,969
Other receivables
994
-17
63
228
Inventories
7,415
-2,007
3,096
5,747
Prepaid expenses and other current assets
-144
-230
-553
-1,250
Other assets
14
20
0
-3
Accounts payable
4,611
7,709
439
11,490
Change in operating leases
-186
-178
-154
-120
Accrued expenses and other current liabilities
3,918
-2,837
127
2,262
Other non-current liabilities
0
84
2
-97
Sales of marketable securities/investments
-
0
0
0
Net cash and cash equivalents used in operating activities
-2,215
3,233
-12,630
-15,190
Purchases of property and equipment
1,042
1,060
604
1,536
Proceeds from asset disposition
0
0
0
126
Net cash and cash equivalents used in investing activities
-1,042
-1,060
-604
-1,410
Proceeds from private placement, net of offering costs
0
0
0
15,359
Proceeds from at-the-market offering, net of offering costs
-
3,889
7,612
2,340
Proceeds from employee stock purchase plan
220
0
151
-
Payments made for financing of insurance payments
260
300
235
456
Payment of deferred consideration liability for acquisition
-
50
0
0
Principal payments on long-term debt
0
0
0
20,000
Principal payments on financing leases
9
9
8
20
Common stock issued for warrants exercised
-
132
385
-
Common stock issued for options exercised
21
72
2,695
-
Net cash and cash equivalents used in financing activities
-28
3,734
10,600
-2,777
Net decrease in cash and cash equivalents
-3,285
5,907
-2,634
-19,377
Cash and cash equivalents at beginning of period
33,565
27,658
49,669
-
Cash and cash equivalents at end of period
30,280
33,565
27,658
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$3,285K
Accounts payable
$4,611K
Accrued expenses and
other current...
$3,918K
Share-based compensation
$1,686K
Depreciation and
amortization
$1,616K
Amortization of debt issuance
costs and debt...
$1,211K
Accounts receivable
-$864K
Prepaid expenses and
other current assets
-$144K
Proceeds from employee
stock purchase plan
$220K
Common stock issued for
options exercised
$21K
Net cash and cash
equivalents used in...
-$2,215K
Net cash and cash
equivalents used in...
-$1,042K
Net cash and cash
equivalents used in...
-$28K
Canceled cashflow
$14,050K
Canceled cashflow
$241K
Inventories
$7,415K
Purchases of property and
equipment
$1,042K
Payments made for
financing of insurance...
$260K
Change in fair value of
liability classified...
$4,996K
Net loss
-$2,492K
Other receivables
$994K
Change in operating
leases
-$186K
Change in fair value of
liability classified...
-$168K
Other assets
$14K
Principal payments on
financing leases
$9K
Buy us a coffee